Patents by Inventor Clarke B. Taylor

Clarke B. Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20220388964
    Abstract: The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.
    Type: Application
    Filed: April 13, 2020
    Publication date: December 8, 2022
    Inventors: Savithri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Eric Talbot, Chris Thomson, Thomas Daniel Aicher, Fernando Padilla, Clarke B. Taylor, Peter L. Toogood
  • Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 11059796
    Abstract: The invention provides aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: July 13, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
    Publication number: 20210061778
    Abstract: The invention provides aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: March 9, 2020
    Publication date: March 4, 2021
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10611740
    Abstract: The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: April 7, 2020
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
    Patent number: 10532088
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 14, 2020
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • Tetrahydroquinoline sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10442798
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: October 15, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10421751
    Abstract: The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 24, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • N-substituted pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 10392350
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: August 27, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor
  • Tetrahydroquinoline sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10364237
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20190175556
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: June 13, 2019
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
    Publication number: 20190135768
    Abstract: The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: June 10, 2016
    Publication date: May 9, 2019
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Benzenesulfonamido and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10189777
    Abstract: The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: January 29, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor, Chad A. Van Huis
  • PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20180334438
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: March 14, 2018
    Publication date: November 22, 2018
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Trifluoromethyl pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 10085972
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 2, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
    Publication number: 20180265502
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: February 7, 2018
    Publication date: September 20, 2018
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20180222867
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: February 14, 2018
    Publication date: August 9, 2018
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor
  • TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
    Publication number: 20180208587
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: December 20, 2017
    Publication date: July 26, 2018
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE
    Publication number: 20180111922
    Abstract: The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: May 5, 2016
    Publication date: April 26, 2018
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9932313
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 3, 2018
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Indazole guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9920012
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: March 20, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis